Angiotech Pharmaceuticals, Inc.
Vancouver V6A1B6 CAN
Share:
Angiotech Receives European Approval for Quill-® SRS Wound Closure Product
New Class of Wound Closure Product Expected to Launch in Europe Mid-Year VANCOUVER, May 17 -- Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX:)(NASDAQ:ANP), a global specialty pharmaceutical and medical device company today announced that is has received European approval for CE mark of its QuillÃ-® Self-Retaining System (SRS). Launched early in the year in the United States,...
Read More »Angiotech's Corporate Partner, Boston Scientific, Announces Japanese Launch of TAXUS-® Express2(TM) Coronary Stent System
Reimbursement granted by National Health Insurance System VANCOUVER, May 8 // -- Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX:)(NASDAQ:ANP), a global specialty pharmaceutical and medical device company, along with its corporate partner Boston Scientific Corporation (NYSE: BSX) today announced the launch of its TAXUS(R) Express2(TM) paclitaxel-eluting coronary stent system in Japan....
Read More »Angiotech Receives European Approval for Quill-® SRS Wound Closure Product
New Class of Wound Closure Product Expected to Launch in Europe Mid-Year VANCOUVER, May 17 -- Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX:)(NASDAQ:ANP), a global specialty pharmaceutical and medical device company today announced that is has received European approval for CE mark of its QuillÃ-® Self-Retaining System (SRS). Launched early in the year in the United States,...
Read More »Angiotech's Corporate Partner, Boston Scientific, Announces Japanese Launch of TAXUS-® Express2(TM) Coronary Stent System
Reimbursement granted by National Health Insurance System VANCOUVER, May 8 // -- Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX:)(NASDAQ:ANP), a global specialty pharmaceutical and medical device company, along with its corporate partner Boston Scientific Corporation (NYSE: BSX) today announced the launch of its TAXUS(R) Express2(TM) paclitaxel-eluting coronary stent system in Japan....
Read More »Angiotech to Market Vascular Wrap(TM)/e0PTFE Graft Combination Product through its Own European Sales and Distribution Networks
VANCOUVER, May 10 / -- Angiotech Pharmaceuticals, Inc., a global specialty pharmaceutical and medical device company, today announced that it has amended its agreement with Edwards Lifesciences Corporation ( Edwards ), regarding the distribution of Angiotech's Vascular Wrap(TM) paclitaxel-eluting mesh/ePTFE graft combination product. Angiotech now has the exclusive rights to distribute the...
Read More »